GlassScriptPhysician profile
Anne S Egem
NPI 1528303781
$756.10
in general payments reported to CMS, 2019-2025
12 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $221 · 2024: $84.67 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $168.67 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $154.17 | 2023-2025 | |
| Viiv Healthcare Company | $124.96 | 2025 | Apretude |
| Idorsia Pharmaceuticals US INC | $103.56 | 2023 | Quviviq |
| Lilly USA, LLC | $59.84 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $25.98 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $25.95 | 2024 | |
| Intercept Pharmaceuticals, INC. | $23.22 | 2024 | |
| Axsome Therapeutics, INC. | $20.59 | 2025 | Auvelity |
| Genzyme Corporation | $18.39 | 2025 | |
| Amgen INC. | $15.39 | 2025 | Repatha, Otezla |
| Novo Nordisk INC | $15.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Egem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.